Developer docs
API playgroundTry for free, no card

Search company profiles

Nectin Therapeutics

Full company profile

uuid0000xvs

Namestring
Nectin Therapeutics
Legal namestring
Nectin Therapeutics Ltd
Websiteurl
nectintx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Nectin Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Jerusalem, Israel, with a US subsidiary in Fort Lee, NJ. The company develops next-generation immuno-oncology therapies targeting the nectin pathway—most notably PVR (CD155)—a checkpoint mechanism implicated in resistance to approved immune checkpoint inhibitors. Approximately 80% of cancer patients do not respond to existing IO drugs, and Nectin is explicitly positioned to address this resistance segment with first-in-class antibodies and antibody-drug conjugates (ADCs).

The company's core pipeline comprises three programs: NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1a/1b trials both as monotherapy and in combination with MSD/Merck's Keytruda (pembrolizumab), with 91 patients enrolled and confirmed partial responses observed across gastric, bladder, NSCLC, head and neck, and melanoma indications; a portfolio of ADC candidates in IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific antibody in lead-selection. The platform originated from research at Hebrew University of Jerusalem and University of Rijeka and has attracted strategic clinical and capital partnerships with MD Anderson, MSD/Merck, Immunome, and multiple Israeli and international biotech investors.

Nectin is pre-revenue with a stated model of advancing assets through clinical development toward licensing or commercialization. The company has raised approximately $46M in disclosed equity funding plus an EIC Accelerator grant, employs 11–50 staff, and distributes visibility primarily through scientific conference presentations (notably ASCO 2026), peer-reviewed publications, and pharma trade press. End customers are oncology patients with advanced solid tumors (and increasingly hematological malignancies), served indirectly via clinical trial sites and, post-approval, through pharmaceutical partnership channels rather than direct sales.

Short descriptiontext

Nectin Therapeutics is a clinical-stage Israeli biotech developing first-in-class immuno-oncology antibodies and ADCs that target the PVR (CD155) checkpoint to overcome resistance in advanced solid tumors and hematological malignancies, with lead asset NTX1088 in Phase 1.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, antibody-drug conjugates, monoclonal antibody development, cancer immunotherapy pipeline, PVR checkpoint inhibitors
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
Product category
Immuno-Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Stage Development
TypeOne Time License
Description

Pre-revenue biotech company. Generating revenue through successful clinical development, regulatory approvals, and eventual product commercialization or licensing deals with pharmaceutical partners.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nectin Therapeutics develops a pipeline of immuno-oncology antibodies and antibody-drug conjugates targeting the nectin/PVR pathway to overcome resistance to existing cancer immunotherapies. Lead asset NTX1088 is a first-in-class anti-PVR (CD155) monoclonal antibody currently in Phase 1 clinical trials as monotherapy and in combination with pembrolizumab (Keytruda). The company also advances ADC candidates in IND-enabling studies and NTX3A13, a multispecific therapeutic antibody in lead selection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Confirmed partial responses observed in evaluable patients across multiple cancer types including gastric, bladder, NSCLC, head and neck, and melanoma
+2 more records
Product overview1 text field

Nectin Therapeutics is a biotechnology company developing a diverse pipeline of targeted immunotherapies including novel immuno-oncology (IO) antibodies and antibody-drug conjugates (ADCs). The company's core products include NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1 clinical trials; ADC Candidates undergoing IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific therapeutic antibody in lead-selection stage. The company focuses on addressing resistance mechanisms to current immune oncology treatments.

Product and service3 records
1NTX1088
CategoryImmuno-oncology antibody
Description

A first-in-class monoclonal antibody directed against PVR (CD155), a key immune checkpoint, currently in Phase 1 clinical trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for patients with advanced solid tumors.

2ADC Candidates
CategoryAntibody-drug conjugates
Description

Pipeline of first-in-class and best-in-class antibody-drug conjugate (ADC) therapies for solid and hematological malignancies; candidates have demonstrated robust tumor regression in multiple in vivo models and programs are undergoing IND-enabling studies.

3NTX3A13
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Immunome partnered with Nectin to access Nectin's antibodies for next-generation ADC development, leveraging Nectin's novel antibody technology in ADC programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-30
Description

MD Anderson's VC arm joined the $25M Series A funding round and entered into clinical trial collaboration for NTX1088. The partnership involves conducting Phase 1 clinical trials at MD Anderson sites for the company's first-in-class anti-PVR immunotherapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Entered clinical trial collaboration agreement with MSD (Merck) to study NTX1088 with KEYTRUDA (pembrolizumab). The combination therapy arm was added to the Phase 1 clinical trial to evaluate the anti-PVR candidate with Keytruda in advanced solid tumors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Company established in 2017 based on seminal research conducted at Hebrew University of Jerusalem, with ongoing research collaboration. Technology addresses major escape mechanisms of current IO therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Company established based on seminal research conducted at University of Rijeka, contributing to the foundational science behind nectin pathway targeting therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-based clinical-stage immuno-oncology biotech developing novel antibody therapeutics targeting the tumor microenvironment. Both companies emerged from Israeli academic research and pursue novel immune checkpoints, making them closely comparable in geography, stage, and therapeutic approach.

TypeDirect peer
Description

Clinical-stage oncology biotech developing conditionally activated IO therapeutics, including INDUKINE molecules designed to overcome the limitations of approved checkpoint inhibitors. Comparable as a Phase 1/2 IO biotech targeting resistance mechanisms with platform technology.

TypeDirect peer
Description

Clinical-stage IO biotech with a pipeline targeting adenosine, TIGIT, and PD-1 pathways with multiple combination strategies including anti-PD-1 partnerships. Comparable in targeting novel IO pathways, partnering with large pharma for combinations, and pursuing the IO-resistant patient population.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and next-generation IO therapeutics, including CTX-009 (anti-DLL4/VEGF) and CTX-1121 (anti-CD19/CD20). Comparable in clinical-stage IO antibody development and combination strategies to overcome resistance to existing therapies.

5Surface Oncology
TypeDirect peer
Description

Clinical-stage IO biotech developing antibody therapeutics targeting the tumor microenvironment, including IL-27 and CD39 programs. Comparable as a smaller clinical-stage IO company focused on novel immune checkpoints with combination therapy approaches.

TypeDirect peer
Description

Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune stimulants. Comparable in developing novel antibody-based oncology therapeutics at clinical stage with platform technology for solid tumors.

TypeDirect peer
Description

Clinical-stage oncology company developing antibody-drug conjugates (ADCs) and immuno-oncology therapeutics. Comparable in developing ADCs for solid tumors and IO combination approaches at similar clinical stage.

TypeEmerging player
Description

Clinical-stage biotech developing T cell engagers (TriTACs) for solid tumor IO, recently acquired by Merck for approximately $680M. Comparable as a clinical-stage IO antibody developer with pharma acquisition appeal, particularly given Nectin's existing MSD collaboration.

TypeEmerging player
Description

Clinical-stage biotech developing conditionally active T cell engagers for solid tumors, including COBRA platform for tumor-specific activation. Comparable as a smaller platform-based antibody developer targeting solid tumors with novel immune engagement approaches.

TypeBroad incumbent
Description

Established ADC-focused oncology company acquired by AbbVie for $10.1B in 2024. Comparable as an ADC developer targeting solid tumors with multiple clinical-stage programs; provides context for potential strategic exit value for Nectin's ADC platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nectin Therapeutics

Immuno-Oncology Therapeuticsnectintx.com

Nectin Therapeutics is a clinical-stage Israeli biotech developing first-in-class immuno-oncology antibodies and ADCs that target the PVR (CD155) checkpoint to overcome resistance in advanced solid tumors and hematological malignancies, with lead asset NTX1088 in Phase 1.

What Nectin Therapeutics does

Nectin Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Jerusalem, Israel, with a US subsidiary in Fort Lee, NJ. The company develops next-generation immuno-oncology therapies targeting the nectin pathway—most notably PVR (CD155)—a checkpoint mechanism implicated in resistance to approved immune checkpoint inhibitors. Approximately 80% of cancer patients do not respond to existing IO drugs, and Nectin is explicitly positioned to address this resistance segment with first-in-class antibodies and antibody-drug conjugates (ADCs).

The company's core pipeline comprises three programs: NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1a/1b trials both as monotherapy and in combination with MSD/Merck's Keytruda (pembrolizumab), with 91 patients enrolled and confirmed partial responses observed across gastric, bladder, NSCLC, head and neck, and melanoma indications; a portfolio of ADC candidates in IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific antibody in lead-selection. The platform originated from research at Hebrew University of Jerusalem and University of Rijeka and has attracted strategic clinical and capital partnerships with MD Anderson, MSD/Merck, Immunome, and multiple Israeli and international biotech investors.

Nectin is pre-revenue with a stated model of advancing assets through clinical development toward licensing or commercialization. The company has raised approximately $46M in disclosed equity funding plus an EIC Accelerator grant, employs 11–50 staff, and distributes visibility primarily through scientific conference presentations (notably ASCO 2026), peer-reviewed publications, and pharma trade press. End customers are oncology patients with advanced solid tumors (and increasingly hematological malignancies), served indirectly via clinical trial sites and, post-approval, through pharmaceutical partnership channels rather than direct sales.

Nectin Therapeutics firmographics

Firmographics
Name
Nectin Therapeutics
Legal name
Nectin Therapeutics Ltd
Website
https://nectintx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Nectin Therapeutics is a clinical-stage Israeli biotech developing first-in-class immuno-oncology antibodies and ADCs that target the PVR (CD155) checkpoint to overcome resistance in advanced solid tumors and hematological malignancies, with lead asset NTX1088 in Phase 1.
Ownership category
akta.pro rank

Nectin Therapeutics industry classification

Industry
Product category
Immuno-Oncology Therapeutics
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Immuno-oncology therapeutics
  • Antibody-drug conjugates
  • Monoclonal antibody development
  • Cancer immunotherapy pipeline
  • PVR checkpoint inhibitors

Where Nectin Therapeutics is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Nectin Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Clinical Stage Development: Pre-revenue biotech company. Generating revenue through successful clinical development, regulatory approvals, and eventual product commercialization or licensing deals with pharmaceutical partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Nectin Therapeutics product offering

Product offering

Core offering

Nectin Therapeutics develops a pipeline of immuno-oncology antibodies and antibody-drug conjugates targeting the nectin/PVR pathway to overcome resistance to existing cancer immunotherapies. Lead asset NTX1088 is a first-in-class anti-PVR (CD155) monoclonal antibody currently in Phase 1 clinical trials as monotherapy and in combination with pembrolizumab (Keytruda). The company also advances ADC candidates in IND-enabling studies and NTX3A13, a multispecific therapeutic antibody in lead selection.

Product overview

Nectin Therapeutics is a biotechnology company developing a diverse pipeline of targeted immunotherapies including novel immuno-oncology (IO) antibodies and antibody-drug conjugates (ADCs). The company's core products include NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1 clinical trials; ADC Candidates undergoing IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific therapeutic antibody in lead-selection stage. The company focuses on addressing resistance mechanisms to current immune oncology treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTX1088 A first-in-class monoclonal antibody directed against PVR (CD155), a key immune checkpoint, currently in Phase 1 clinical trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for patients with advanced solid tumors.
  • ADC Candidates Pipeline of first-in-class and best-in-class antibody-drug conjugate (ADC) therapies for solid and hematological malignancies; candidates have demonstrated robust tumor regression in multiple in vivo models and programs are undergoing IND-enabling studies.
  • NTX3A13

Quantifiable outcome

  • Confirmed partial responses observed in evaluable patients across multiple cancer types including gastric, bladder, NSCLC, head and neck, and melanoma
  • +2 more outcomes

Companies that use Nectin Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Nectin Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nectin Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • ImmunomeminorStrategic or Co-development Partner · 1 January 2024Immunome partnered with Nectin to access Nectin's antibodies for next-generation ADC development, leveraging Nectin's novel antibody technology in ADC programs.
  • MD Anderson Cancer CentercoreStrategic or Co-development Partner · 30 November 2022MD Anderson's VC arm joined the $25M Series A funding round and entered into clinical trial collaboration for NTX1088. The partnership involves conducting Phase 1 clinical trials at MD Anderson sites for the company's first-in-class anti-PVR immunotherapy.
  • MSD (Merck)coreStrategic or Co-development Partner · 1 January 2022Entered clinical trial collaboration agreement with MSD (Merck) to study NTX1088 with KEYTRUDA (pembrolizumab). The combination therapy arm was added to the Phase 1 clinical trial to evaluate the anti-PVR candidate with Keytruda in advanced solid tumors.
  • Hebrew University of JerusalemcoreStrategic or Co-development Partner · 1 January 2017Company established in 2017 based on seminal research conducted at Hebrew University of Jerusalem, with ongoing research collaboration. Technology addresses major escape mechanisms of current IO therapies.
  • University of RijekacoreStrategic or Co-development Partner · 1 January 2017Company established based on seminal research conducted at University of Rijeka, contributing to the foundational science behind nectin pathway targeting therapies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Nectin Therapeutics competitors and assessment

Company assessment

Direct peers

  • Compugen: Israel-based clinical-stage immuno-oncology biotech developing novel antibody therapeutics targeting the tumor microenvironment. Both companies emerged from Israeli academic research and pursue novel immune checkpoints, making them closely comparable in geography, stage, and therapeutic approach.
  • Werewolf Therapeutics: Clinical-stage oncology biotech developing conditionally activated IO therapeutics, including INDUKINE molecules designed to overcome the limitations of approved checkpoint inhibitors. Comparable as a Phase 1/2 IO biotech targeting resistance mechanisms with platform technology.
  • Arcus Biosciences: Clinical-stage IO biotech with a pipeline targeting adenosine, TIGIT, and PD-1 pathways with multiple combination strategies including anti-PD-1 partnerships. Comparable in targeting novel IO pathways, partnering with large pharma for combinations, and pursuing the IO-resistant patient population.
  • Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies and next-generation IO therapeutics, including CTX-009 (anti-DLL4/VEGF) and CTX-1121 (anti-CD19/CD20). Comparable in clinical-stage IO antibody development and combination strategies to overcome resistance to existing therapies.
  • Surface Oncology: Clinical-stage IO biotech developing antibody therapeutics targeting the tumor microenvironment, including IL-27 and CD39 programs. Comparable as a smaller clinical-stage IO company focused on novel immune checkpoints with combination therapy approaches.
  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune stimulants. Comparable in developing novel antibody-based oncology therapeutics at clinical stage with platform technology for solid tumors.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates (ADCs) and immuno-oncology therapeutics. Comparable in developing ADCs for solid tumors and IO combination approaches at similar clinical stage.

Emerging players

  • Harpoon Therapeutics: Clinical-stage biotech developing T cell engagers (TriTACs) for solid tumor IO, recently acquired by Merck for approximately $680M. Comparable as a clinical-stage IO antibody developer with pharma acquisition appeal, particularly given Nectin's existing MSD collaboration.
  • Maverick Therapeutics: Clinical-stage biotech developing conditionally active T cell engagers for solid tumors, including COBRA platform for tumor-specific activation. Comparable as a smaller platform-based antibody developer targeting solid tumors with novel immune engagement approaches.

Broad incumbents

  • ImmunoGen: Established ADC-focused oncology company acquired by AbbVie for $10.1B in 2024. Comparable as an ADC developer targeting solid tumors with multiple clinical-stage programs; provides context for potential strategic exit value for Nectin's ADC platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nectin Therapeutics social profiles

Digital presence

Nectin Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nectin Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Nectin Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nectin Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nectin Therapeutics

What does Nectin Therapeutics do?

Nectin Therapeutics develops a pipeline of immuno-oncology antibodies and antibody-drug conjugates targeting the nectin/PVR pathway to overcome resistance to existing cancer immunotherapies. Lead asset NTX1088 is a first-in-class anti-PVR (CD155) monoclonal antibody currently in Phase 1 clinical trials as monotherapy and in combination with pembrolizumab (Keytruda). The company also advances ADC candidates in IND-enabling studies and NTX3A13, a multispecific therapeutic antibody in lead selection.

Is Nectin Therapeutics a public or private company?

Nectin Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nectin Therapeutics founded?

Nectin Therapeutics was founded in 2017. It employs 1 to 10 people.

Where is Nectin Therapeutics based?

Nectin Therapeutics is headquartered in Jerusalem, Israel, in the Middle East region.

How does Nectin Therapeutics make money?

One revenue line is on record: clinical Stage Development.

Who are Nectin Therapeutics's main competitors?

Direct peers on record are Compugen, Werewolf Therapeutics, Arcus Biosciences, Compass Therapeutics, Surface Oncology, Bolt Biotherapeutics and Pyxis Oncology. Emerging players are Harpoon Therapeutics and Maverick Therapeutics. ImmunoGen is listed as a broad incumbent.

Does Nectin Therapeutics have an API?

No public API is recorded for Nectin Therapeutics.

What industry is Nectin Therapeutics in?

Nectin Therapeutics's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAMAK, Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026Nectin Therapeutics presented Phase 1a/1b clinical data for NTX1088, a first-in-class anti-CD155 antibody, in combination with pembrolizumab (Keytruda) at ASCO 2026, demonstrating favorable safety and preliminary anti-tumor activity in 91 patients with advanced solid tumors. Among 41 evaluable patients receiving active dose levels, confirmed partial responses were observed across multiple difficult-to-treat cancers including gastric, bladder, non-small cell lung, head and neck, and melanoma, with a recommended dose of 1,750 mg established. The company plans further clinical evaluation in Phase 2 studies including less heavily pretreated and biomarker-enriched patient populations.PR NewswireNectin Therapeutics Licenses Novel Antibodies to ImmunomeNectin Therapeutics announced a global, exclusive license agreement with Immunome Inc. for a panel of monoclonal antibodies targeting an undisclosed cancer-related molecule. Immunome will handle all research, development, manufacturing, and commercialization activities, while Nectin receives an upfront payment along with potential milestone payments and royalties. The agreement enables Nectin to concentrate on its anti-PVR program NTX-1088 and advance its ADC pipeline while leveraging Immunome's experience in developing and commercializing antibody drug conjugate therapies.PR NewswireGIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug ConjugatesGuangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics Ltd to support the ongoing clinical development of its lead program targeting PVR and multiple ADC candidates. This funding will help advance Nectin's NTX1088 global Phase 1 clinical trial and develop its anti-drug conjugate portfolio. Nectin's innovative therapies aim to improve cancer treatment outcomes by addressing resistance to existing immune oncology treatments.PR NewswireNectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid TumoNectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate its novel anti-PVR antibody NTX1088 in combination with KEYTRUDA (pembrolizumab) for treating patients with locally advanced and metastatic solid tumors. The Phase 1 trial (NCT05378425/KEYNOTE-E92) includes a dose escalation stage followed by an expansion stage in 90 patients, investigating NTX1088 both as a single agent and in combination with KEYTRUDA. PVR (CD155) is overexpressed in multiple solid tumor types and is associated with resistance to PD1 and PDL1 inhibitors, making it a compelling therapeutic target for addressing treatment resistance.IFTTTIsraeli co Nectin Therapeutics raises $25mNectin Therapeutics raised $25 million in a Series A led by IBF and Peregrine Ventures. The company also dosed the first patient in its Phase I trial of NTX1088, a PVR blocker, in cancer patients. The trial will include up to 90 patients.PR NewswireNectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for TreatmeNectin Therapeutics has initiated patient dosing in a Phase 1 clinical trial of NTX1088, its first-in-class PVR-targeted immunotherapy for locally advanced and metastatic solid tumors, at MD Anderson Cancer Center with investment from Cancer Focus Fund. The company has simultaneously extended its Series A financing to over $25 million, with new investor Israel Biotech Fund joining existing investors aMoon Fund and Peregrine Ventures. The funding will support the clinical evaluation of NTX1088 and advance Nectin's broader pipeline of targeted immunotherapies and antibody-drug conjugates.BioSpaceNectin’s Series A Hits $25M as Investors Support New Target for Solid TumorsNectin Therapeutics has initiated the dosing of the first solid tumor patient in a Phase I clinical trial for their monoclonal antibody, NTX1088, while successfully expanding their Series A funding to over $25 million. The trial, taking place at the MD Anderson Cancer Center, is aimed at patients with locally advanced and metastatic solid tumors, particularly focusing on those with high levels of PVR and PD-L1 expression. This innovative approach in targeting PVR may offer new hope for cancer patients who typically do not benefit from existing immunotherapies.PR NewswireNectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted ImmunotherapyNectin Therapeutics announced a $5.4 million investment from Cancer Focus Fund to finance the Phase 1 clinical trial of its first-in-class anti-PVR immunotherapy, NTX1088. The study, which will be conducted at MD Anderson Cancer Center starting in mid-2022, aims to assess the safety and efficacy of NTX1088 in patients with locally advanced and metastatic solid tumors. This funding supports the development of a novel treatment designed to overcome resistance to current immune oncology therapies.CTechIsraeli healthtech VC aMoon Velocity invests $6 million in Nectin TherapeuticsaMoon Velocity invested $6 million in Nectin Therapeutics, with Integra Holdings participating, bringing total funding to $15 million. Nectin Therapeutics develops monoclonal antibodies targeting Nectin proteins to boost immune response against cancers. The company is in advanced development stages of its antibodies.IFTTTIsraeli immuno-oncology co Nectin raises $6mNectin Therapeutics completed a $6 million financing round led by aMoon Velocity, with Integra Holdings participating. The company plans to raise $15 million total to develop monoclonal antibodies targeting the Nectin family of proteins. The antibodies aim to boost the immune system's ability to fight cancers.